We rank companies based on fund manager, research analyst and news sentiment
GDTC stock icon

CytoMed Therapeutics Limited Ordinary Shares
GDTC

$2.1
0.24%
 

About: CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.

Employees: 27

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

4% more capital invested

Capital invested by funds: $20.7K [Q3] → $21.5K (+$802) [Q4]

0% more funds holding

Funds holding: 2 [Q3] → 2 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.01% less ownership

Funds ownership: 0.05% [Q3] → 0.04% (-0.01%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$5
138%
upside
Avg. target
$5
138%
upside
High target
$5
138%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Benchmark
Bruce Jackson
138%upside
$5
Speculative Buy
Reiterated
4 Dec 2023

Financial journalist opinion